In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of treatment. “It’s quite remarkable,” said Paul Mulholland, consultant oncologist at University College Hospital London, and chief investigator of the Phase I study. The trial will recruit patients with recurrent disease who have undergone surgery to remove as much of the tumor as possible; the radiopharmaceutical is delivered weekly via a small implant under the scalp.
Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025
Radioligand therapies offer a resistance-proof mechanism that complements immuno-therapies and other drug classes. No wonder oncology players continue to pile in.
More from Outlook
• By
The financial macroenvironment may be looking more favorable for 2025 but will pharma growth be muted by elements beyond its control? In Vivo discusses the headwinds and drivers for pharma in the coming 12 months.
• By
Despite the stellar success of the class so far, biotech is now looking past GLP-1s to more tolerable, sustainable approaches to obesity.
• By
Former Roche CEO Bill Burns reflects on transforming Roche into a global leader in specialty care and oncology. Now, as he spearheads efforts to combat antibiotic resistance, Burns shares insights on industry evolution, the power of cultural change, and the urgent need for a new business model in antibiotics development.
• By
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
More from Market Intelligence
• By
Biotech BPGbio applies causal AI to generate insights from samples from what the CEO says is one of the world's largest biobanks. With several promising late-stage programs, its platform seems to be yielding fruit.
• By
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
• By
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.